URGN UroGen Pharma Ltd.
$33.91▼ -0.38%
Healthcare
Other
After hours
$33.91▲ +0.00%
Oct 27, 5:23 PM ET
Volume 1.03M
Avg Volume (10D) 842.5K
Key Metrics & Fundamentals
Market Cap
$1.66B
P/E Ratio
–
Div Yield
0.00%
52W Range
16.50 - 50.81
% vs 50 MA
-18.02%
% vs 200 MA
9.01%
RSI-14
30.0
MACD Histogram
-0.1700
Beta (1Y vs SPY)
1.21
Free Cash Flow
-$33.07M
Gross Rev
$72.46M
Gross Profit
$65.88M
EBITDA
-$3.17M
COGS
$6.57M
Operating Exp
$65.77M
Operating Income
$111,000
EBIT
$111,000
Pretax Income
-$8.72M
Net Income
-$14.35M
EPS (Diluted)
-0.28
Price & Volume History
Loading chart…
Recent News
UroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026
GlobeNewswire · Oct 27, 2026 6:00 PM ET
Why UroGen Pharma (URGN) Is Getting Fresh Attention Now
Simply Wall St. · Oct 20, 2026 6:17 PM ET
UroGen Pharma Says FDA Accepts New Drug Application for UGN-103 in Bladder Cancer
MT Newswires · Oct 19, 2026 9:07 AM ET
UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBC
GlobeNewswire · Oct 19, 2026 8:00 AM ET
Here's Why You Should Add URGN Stock to Your Portfolio Now
Zacks · Sep 30, 2026 9:11 AM ET
UroGen Pharma (URGN) Stock Looks Fairly Valued On Its Sales Base
Simply Wall St. · Sep 25, 2026 3:09 AM ET
Is Establishment Labs’ (ESTA) Profitability Inflection the Ultimate Buying Opportunity?
Insider Monkey · Sep 23, 2026 3:32 PM ET
Is UroGen’s (URGN) Commercial Engine Strong Enough To Fund Its Pipeline Ambitions?
Insider Monkey · Sep 23, 2026 9:13 AM ET
Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress
Barrons.com · Sep 9, 2026 10:44 AM ET
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Sep 4, 2026 8:00 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See URGN's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.